Abstract 3169
Background
Immunotherapy (IO) has brought dramatic clinical benefits to patients with mRCC. Most patients tolerate IO, but serious irAE have been reported. Some studies indicate the correlation of irAEs and clinical response in other cancer types such as lung cancer and melanoma. For mRCC, the impact of irAE on clinical outcome is unknown.
Methods
A retrospective review of patients with mRCC treated with nivolumab as standard of care between March 2017-January 2018 from 13 Italian centers of the IGO group (Innovators in Genitourinary Oncology) was performed. Patients enrolled in clinical trial or expanded access program were excluded. IrAEs were assessed based on the treating physician diagnosis.
Results
A total of 111 patients (pts) met criteria. Median age was 67 yr, 83 pts (75%) were male. Histology was clear cell in 102 pts (92%) and non clear cell in 9 pts (8%). IrAE was noted in 48 pts (43%) with steroid required in 21 pts (44%). The time from the beginning of nivolumab treatment to the irAE occurrence ranged 1-81 weeks (mean 10 weeks). Most patients received nivolumab as a second or third line of treatment (61% and 37% respectively). The most common irAEs were cutaneous (21%), endocrinologic (17%), gastrointestinal and pulmonary (both 15%). In patients who developed irAE, 2% of complete response (CR), 22% of partial response (PR), 41% of stable disease (SD) and 35% of progression disease (PD) (according to RECIST criteria) were observed versus 0% CR, 7% PR, 37% SD and 57% PD in patients who did not develop irAE. Development of irAE had a statistically significant impact on response rates (p = 0.007). There was also no significant association of steroid use with response rates (p = 0.643). Because of the short follow up, survival data were not mature at the time of the analysis.
Conclusions
The development of irAE may be correlated with better response to nivolumab. This data may be limited by sample size and retrospective nature. A long-term follow-up is required to determine the impact of irAE on survival in mRCC patients treated with nivolumab.
Clinical trial identification
Legal entity responsible for the study
Maria Giuseppa Vitale.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
M.G. Vitale: Advisory boards, speaker or investigator: Bristol-Myers Squibb. R. Sabbatini: Advisory boards, honoraria or study participation: Bristol-Myers Squib. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract